Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas

NCT02784015 Phase 2 UNKNOWN

To evaluate the treatment outcome of unresectable soft tissue sarcoma using response based treatment

Details

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	UNKNOWN
Enrolment	41
Start date	2016-05
Completion	2023-05

Conditions

• Unresectable Localized Soft Tissue Sarcoma

Interventions

• Cisplatin
• Etoposide
• Doxorubicin
• Cyclophosphamide
• Ifosfamide
• Carboplatin
• Radiotherapy
• Thiotepa
• Melphalan

Primary outcomes

• Rate of event free survival — Up to 3 years

Countries

South Korea